Rapport Therapeutics (NASDAQ:RAPP) Director Buys 3,600 Shares of Company Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Ramiro Sanchez purchased 3,600 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The shares were purchased at an average cost of $27.35 per share, with a total value of $98,460.00. Following the completion of the purchase, the director owned 3,600 shares of the company’s stock, valued at $98,460. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Rapport Therapeutics Stock Down 2.3%

NASDAQ RAPP traded down $0.60 during trading on Friday, hitting $25.93. 1,180,713 shares of the stock traded hands, compared to its average volume of 410,900. Rapport Therapeutics, Inc. has a 12-month low of $23.75 and a 12-month high of $52.93. The firm has a 50-day simple moving average of $39.44 and a 200-day simple moving average of $39.02. The company has a market capitalization of $1.24 billion, a P/E ratio of -8.53 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, research analysts predict that Rapport Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on RAPP shares. Citigroup reaffirmed an “outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Rapport Therapeutics in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, October 15th. JonesTrading boosted their target price on shares of Rapport Therapeutics from $50.00 to $82.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Guggenheim boosted their target price on shares of Rapport Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $68.36.

Institutional Investors Weigh In On Rapport Therapeutics

Several institutional investors have recently modified their holdings of RAPP. KBC Group NV purchased a new position in shares of Rapport Therapeutics in the 1st quarter worth approximately $30,000. Sterling Capital Management LLC increased its position in shares of Rapport Therapeutics by 597.9% during the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after purchasing an additional 843 shares during the last quarter. State of Wyoming purchased a new stake in Rapport Therapeutics during the 2nd quarter valued at $65,000. Meeder Asset Management Inc. purchased a new stake in Rapport Therapeutics during the 2nd quarter valued at $116,000. Finally, AlphaCentric Advisors LLC raised its holdings in Rapport Therapeutics by 6.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock valued at $201,000 after buying an additional 408 shares during the period.

Trending Headlines about Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 achieved both Phase 2 endpoints in bipolar mania. The drug produced statistically significant placebo-adjusted improvements in mania measures, and Rapport plans to advance it into Phase 3. The results could substantially expand RAP-219’s market opportunity beyond epilepsy. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain bullish and several raised price targets. JonesTrading increased its target to $82, BTIG Research to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The average analyst target is approximately $68.36, implying substantial upside from recent levels. BTIG Research price target increase
• Positive Sentiment: Company insiders made roughly $1.57 million of open-market purchases. CFO Troy Ignelzi bought 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young and Paul Silva also purchased shares. The concentrated buying may signal management confidence after the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: A valuation analysis argues that RAPP could be approximately 62% below fair value following the Phase 2 data, supporting the bullish case but relying on assumptions about Phase 3 success, approval and future commercialization. Rapport Therapeutics fair value analysis
• Negative Sentiment: Investors still face substantial execution risk. Commentary suggested some portions of the bipolar-mania data narrowly met expectations, potentially limiting enthusiasm after the initial rally. Rapport is also unprofitable, recently missed quarterly EPS estimates and is forecast to post a full-year loss of about $4.09 per share. The shares remain far below their 52-week high and below their 50-day and 200-day moving averages. Rapport Therapeutics bipolar data analysis

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.